Last reviewed · How we verify

Midazolam+Fentanyl Combination

Universidad de Cartagena · FDA-approved active Small molecule

Midazolam and fentanyl work synergistically as a benzodiazepine and opioid combination to produce sedation, analgesia, and anxiolysis through GABA and opioid receptor agonism.

Midazolam and fentanyl work synergistically as a benzodiazepine and opioid combination to produce sedation, analgesia, and anxiolysis through GABA and opioid receptor agonism. Used for Procedural sedation and analgesia, Critical care sedation, Preoperative anxiolysis and analgesia.

At a glance

Generic nameMidazolam+Fentanyl Combination
Also known asMidazolam, Fentanyl
SponsorUniversidad de Cartagena
Drug classBenzodiazepine + Opioid combination
TargetGABA-A receptor (midazolam); Mu-opioid receptor (fentanyl)
ModalitySmall molecule
Therapeutic areaAnesthesia, Sedation, Pain Management
PhaseFDA-approved

Mechanism of action

Midazolam is a short-acting benzodiazepine that enhances GABAergic inhibitory neurotransmission in the central nervous system, producing sedation and anxiolysis. Fentanyl is a potent synthetic opioid agonist that binds to mu-opioid receptors to produce analgesia and respiratory depression. The combination is used to achieve rapid onset sedation with concurrent pain relief, commonly employed in procedural and critical care settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: